A case of gastric polyposis in antral area of stomach following prolonged proton-pump therapy

Alqutub, Adel; Masoodi, Ibrahim

doi:10.3205/000108

Cited by 7 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FGP can be either sporadic or syndromic [2,3]. Sporadic polyps are usually less than ten, while in syndromic cases, the number of polyps is many, with associated dysplasia and risk of malignant transformation in 50 to 100% of cases [3].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathologic Correlation of Large Gastric Polyps in an Elderly Female: Case Report and Review of the Literature

Taleb,

Awosusi

2024

Cureus

View full text Add to dashboard Cite

Fundic gland polyps (FGPs) are benign epithelial polyps usually located in the gastric body and fundus. Here, we describe the case of an elderly woman who presented with symptomatic anemia, abdominal pain, and weight loss. There was also history of chronic use of proton pump inhibitors for the symptomatic treatment of dyspepsia. Reflux esophagitis, duodenal ulcers, and multiple gastric polyps suspicious of malignancy were found at endoscopy. A large pedunculated antral polyp measuring more than 10mm in the largest dimension and other smaller polyps in the body and fundus were removed completely by cold snare and sent for histopathologic evaluation. The polyps were eventually diagnosed as benign fundic gland polyps. Biopsies taken from the gastric mucosa also showed Helicobacter pylori-associated gastritis. Helicobacter pylori eradication therapy was commenced with the resultant resolution of symptoms. No surveillance is required for FGPs because they are not premalignant lesions. However, large FGPs require excision and thorough histopathologic evaluation to rule out atypia and malignancy. This index case further highlights a possible causal link between the chronic use of proton pump inhibitors and the development of fundic gland polyps.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinicopathologic Correlation of Large Gastric Polyps in an Elderly Female: Case Report and Review of the Literature

Taleb,

Awosusi

2024

Cureus

View full text Add to dashboard Cite

show abstract

“…PPI‐induced gastric hyperplastic polyps usually regress after cessation of PPI therapy. 40 , 44 , 45 If gastric hyperplastic polyps <1 cm developed during VPZ/PPI therapy, cessation of VPZ/PPI is not mandatory. However, gastric hyperplastic polyps >1 cm should be endoscopically resected when they do not regress even with cessation of VPZ/PPI.…”

Section: Introductionmentioning

confidence: 99%

Endoscopic findings and outcomes of gastric mucosal changes relating to potassium‐competitive acid blocker and proton pump inhibitor therapy

Shinozaki,

Osawa,

Miura

et al. 2024

DEN Open

View full text Add to dashboard Cite

Gastric mucosal changes associated with long‐term potassium‐competitive acid blocker and proton pump inhibitor (PPI) therapy may raise concern. In contrast to that for PPIs, the evidence concerning the safety of long‐term potassium‐competitive acid blocker use is scant. Vonoprazan (VPZ) is a representative potassium‐competitive acid blocker released in Japan in 2015. In order to shed some comparative light regarding the outcomes of gastric mucosal lesions associated with a long‐term acid blockade, we have reviewed six representative gastric mucosal lesions: fundic gland polyps, gastric hyperplastic polyps, multiple white and flat elevated lesions, cobblestone‐like gastric mucosal changes, gastric black spots, and stardust gastric mucosal changes. For these mucosal lesions, we have evaluated the association with the type of acid blockade, patient gender, Helicobacter pylori infection status, the degree of gastric atrophy, and serum gastrin levels. There is no concrete evidence to support a significant relationship between VPZ/PPI use and the development of neuroendocrine tumors. Current data also shows that the risk of gastric mucosal changes is similar for long‐term VPZ and PPI use. Serum hypergastrinemia is not correlated with the development of some gastric mucosal lesions. Therefore, serum gastrin level is unhelpful for risk estimation and for decision‐making relating to the cessation of these drugs in routine clinical practice. Given the confounding potential neoplastic risk relating to H. pylori infection, this should be eradicated before VPZ/PPI therapy is commenced. The evidence to date does not support the cessation of clinically appropriate VPZ/PPI therapy solely because of the presence of these associated gastric mucosal lesions.

show abstract

Sporadic Gastric Hyperplastic Polyposis with Superimposed Multifocal Adenocarcinoma, an Extremely Rare Case Report and Review of the Literature

Geramizadeh

Abbasi

Bananzadeh

et al. 2015

J Gastrointest Canc

View full text Add to dashboard Cite

A case of gastric polyposis in antral area of stomach following prolonged proton-pump therapy

Cited by 7 publications

References 9 publications

Clinicopathologic Correlation of Large Gastric Polyps in an Elderly Female: Case Report and Review of the Literature

Clinicopathologic Correlation of Large Gastric Polyps in an Elderly Female: Case Report and Review of the Literature

Endoscopic findings and outcomes of gastric mucosal changes relating to potassium‐competitive acid blocker and proton pump inhibitor therapy

Sporadic Gastric Hyperplastic Polyposis with Superimposed Multifocal Adenocarcinoma, an Extremely Rare Case Report and Review of the Literature

Contact Info

Product

Resources

About